Drug Trial Radar · NCT02214628
Phase 2A Open Label Safety Study of Fovista® (Anti-PDGF BB) Regimen Administered in Combination With Anti-VEGF Therapy to Study Sub-Retinal Fibrosis in Neovascular AMD
Last checked: Nov 20, 2026Latest source record: Feb 23, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
101
Actual
Start
Jul 2014
Primary completion
Dec 2016
Study completion Dec 2016
Sponsor
- Lead sponsor
- Ophthotech CorporationIndustry
- Sponsor type
- Industry
- First posted
- Aug 12, 2014
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective is to evaluate the safety of intravitreal Fovista® (anti-PDGF BB) administered in combination with anti-VEGF therapy.
Conditions
- Age-related Macular Degeneration
Interventions
Fovista® (anti-PDGF BB) plus anti-VEGFDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Subject With Non Serious Adverse Events (Reported by >5% of Subjects)Time frame: 2 years
- Number of Subjects With Serious Adverse EventsTime frame: 2 years
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Phoenix, Arizona
Site not named
Beverly Hills, California
Site not named
Sacramento, California
Site not named
Sacramento, California
Site not named
Santa Ana, California
Site not named
Augusta, Georgia
Site not named
Oak Forest, Illinois
Site not named
Boston, Massachusetts
Site not named
Jackson, Michigan
Site not named
Minneapolis, Minnesota
Site not named
Cincinnati, Ohio
Site not named
Ladson, South Carolina
Site not named
Abilene, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.